<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01758367</url>
  </required_header>
  <id_info>
    <org_study_id>CN301-XYK-002</org_study_id>
    <nct_id>NCT01758367</nct_id>
  </id_info>
  <brief_title>Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Navy General Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <brief_summary>
    <textblock>
      Decitabine can up-regulate a series of immune associated proteins, including cancer testis&#xD;
      antigens (CTA), major histocompatibility complex (MHC), co-stimulatory molecules and adhesion&#xD;
      molecules, which suggests a potential benefit for a following adoptive T cell therapy. In&#xD;
      addition, decitabine induce FOXP3 expression in CD4+ T cells and convert CD4+ T cells into T&#xD;
      regulatory cells(Tregs). As a result, Graft versus host disease(GVHD) can be reduced by&#xD;
      treatment of decitabine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>3 Years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Recurrent Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Decitabine+DLI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed AML after Allo-HSCT will be treated with decitabine and DLI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deciatbine(DAC)</intervention_name>
    <arm_group_label>Decitabine+DLI</arm_group_label>
    <other_name>5-aza-2'-deoxycytidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 - 60 years&#xD;
&#xD;
          -  Histologically or cytologically documented relapse of acute myeloid leukemia after a&#xD;
             stem cell transplant&#xD;
&#xD;
          -  Must have the ability to observe the efficacy and events&#xD;
&#xD;
          -  Patient must have ability to understand and willingness to provide written informed&#xD;
             consent prior to participation in the study and any related procedures being performed&#xD;
&#xD;
          -  Must have an Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 3&#xD;
&#xD;
          -  Must have suitable donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must not have an advanced malignant hepatic tumor&#xD;
&#xD;
          -  Must not receive any other forms of chemotherapy after cell infusion during the&#xD;
             treatment protocol&#xD;
&#xD;
          -  Must not be receiving any other investigational agents within 14 days of first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Must not have uncontrolled intercurrent illness including ongoing or active infection,&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements&#xD;
&#xD;
          -  Must not be pregnant or breastfeeding; pregnant women are excluded from this study&#xD;
             because decitabine is a Category D agent with the potential for teratogenic or&#xD;
             abortifacient effects; because there is an unknown but potential risk for adverse&#xD;
             events in nursing infants secondary to treatment of the mother with decitabine,&#xD;
             breastfeeding should be discontinued if the mother is treated with decitabine; these&#xD;
             potential risks may also apply to other agents used in this study&#xD;
&#xD;
          -  Must not have a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to decitabine or other agents used in the study&#xD;
&#xD;
          -  Must not have a known or suspected hypersensitivity to decitabine&#xD;
&#xD;
          -  Must not be human immunodeficiency virus (HIV)-positive and on combination&#xD;
             antiretroviral therapy; these patients are ineligible because of the potential for&#xD;
             pharmacokinetic interactions with decitabine; in addition, these patients are at&#xD;
             increased risk of lethal infections when treated with marrow-suppressive therapy;&#xD;
             appropriate studies will be undertaken in patients receiving combination&#xD;
             antiretroviral therapy when indicated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Yu, MD, PhD</last_name>
    <phone>86-010-55499003</phone>
    <email>chunhuiliyu@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li-Xin Wang, MD, PhD</last_name>
    <phone>86-010-66958509</phone>
    <email>wanglixin1991@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yu, MD, PhD</last_name>
      <phone>86-010-55499003</phone>
      <email>chunhuiliyu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Li-Xin Wang, MD, PhD</last_name>
      <phone>86-010-66958509</phone>
      <email>wanglixin1991@sohu.com</email>
    </contact_backup>
    <investigator>
      <last_name>Li Yu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Xin Wang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>December 27, 2012</study_first_submitted>
  <study_first_submitted_qc>December 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2013</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Li Yu</investigator_full_name>
    <investigator_title>Director of Department of Hematology</investigator_title>
  </responsible_party>
  <keyword>demethylating agent</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>decitabine(DAC)</keyword>
  <keyword>donor lymphocyte infusion(DLI)</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

